Are gene mutation (BRAF, KRAS, PTEN, and TP53) analyses required to define type 1 and type 2 ovarian cancers? Or, cell morphology is enough to define ovarian cancer types. Thanks.
morphology-based schemes and histopathology are well accepted by many surgical pathologists for classifying ovarian carcinomas. However mounting clinicopathologic and molecular data provide a robust platform for assessment of the contributions of genetic defects in the response of tumour to conventional and targeted drugs.